These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 1983005)

  • 1. Efficacy and safety of ibopamine in congestive heart failure.
    van Veldhuisen DJ; Girbes AR; Crijns HJ; Smit AJ; de Graeff PA; Lie KI
    J Auton Pharmacol; 1990; 10 Suppl 1():s115-21. PubMed ID: 1983005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Electrophysiologic profile of ibopamine in patients with congestive heart failure and ventricular tachycardia and relation to its effects on hemodynamics and plasma catecholamines.
    Van Veldhuisen DJ; Crijns HJ; Girbes AR; Tobé TJ; Wiesfeld AC; Lie KI
    Am J Cardiol; 1991 Nov; 68(11):1194-202. PubMed ID: 1683146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT).
    van Veldhuisen DJ; Man in 't Veld AJ; Dunselman PH; Lok DJ; Dohmen HJ; Poortermans JC; Withagen AJ; Pasteuning WH; Brouwer J; Lie KI
    J Am Coll Cardiol; 1993 Nov; 22(6):1564-73. PubMed ID: 7901256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of acute and chronic ibopamine administration on resting and exercise hemodynamics, plasma catecholamines and functional capacity of patients with chronic congestive heart failure.
    Dei Cas L; Metra M; Visioli O
    Am J Cardiol; 1992 Sep; 70(6):629-34. PubMed ID: 1354938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemodynamic evaluation during exercise test after acute and chronic ibopamine treatment in patients with congestive heart failure.
    Gavazzi A; Mussini A; Bramucci E
    Arzneimittelforschung; 1986 Feb; 36(2A):366-70. PubMed ID: 3707652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and autonomic effects of ibopamine as adjunct to angiotensin-converting enzyme inhibitors in chronic heart failure.
    Szabó BM; van Veldhuisen DJ; van der Burgh PH; Kruik J; Girbes AR; Lie KI
    J Card Fail; 1996 Sep; 2(3):185-92. PubMed ID: 8891856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haemodynamic evaluation of ibopamine in severe congestive heart failure.
    Reffo GC; Turrin M; Gabellini A; Forattini C
    Eur J Clin Pharmacol; 1984; 26(1):19-22. PubMed ID: 6714289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute haemodynamic effects of ibopamine in patients with severe congestive heart failure.
    Ghirardi P; Brusoni B; Mangiavacchi M; Bianco L; Col J; Metra M; Dei Cas L
    Br J Clin Pharmacol; 1985 May; 19(5):613-8. PubMed ID: 4005102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effects of ibopamine and captopril in mild congestive heart failure. Focus on the long-term effects of inodilation on ventricular arrhythmias.
    Cocchieri M; Alunni GF; Del Favero A; Fortunati F; Bardelli G; Capponi EA; Regi L; Boschetti E
    Cardiology; 1990; 77 Suppl 5():36-42. PubMed ID: 2126222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Ibopamine--clinical results].
    Kleber FX
    Z Kardiol; 1991; 80 Suppl 8():71-6. PubMed ID: 1686695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ibopamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in congestive heart failure.
    Spencer C; Faulds D; Fitton A
    Drugs Aging; 1993; 3(6):556-84. PubMed ID: 7906158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of ibopamine on glomerular filtration rate and plasma norepinephrine remain preserved during prolonged treatment in patients with congestive heart failure.
    Lieverse AG; Girbes AR; Van Veldhuisen DJ; Smit AJ; Zijlstra JG; Meijer S; Lie KI; Reitsma WD
    Eur Heart J; 1995 Jul; 16(7):937-42. PubMed ID: 7498209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemodynamic evaluation of ibopamine in patients with refractory congestive heart failure.
    Humar F; Morgera T; Maras P; Camerini F
    Arzneimittelforschung; 1986 Feb; 36(2A):360-2. PubMed ID: 3707650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of ibopamine plus prazosin in congestive heart failure.
    Naidoo DP; Rocke A; Mitha AS
    S Afr Med J; 1998 Feb; 88 Suppl 1():C25-31. PubMed ID: 9542492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of ibopamine, a dopamine congener, on arrhythmias in heart failure.
    Storstein L
    Cardiology; 1990; 77 Suppl 5():30-5. PubMed ID: 1980632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of ibopamine treatment in patients with advanced heart failure: purpose of a new therapeutic scheme with multiple daily administrations.
    Dei Cas L; Metra M; Nodari S; Visioli O
    J Cardiovasc Pharmacol; 1989; 14 Suppl 8():S111-7. PubMed ID: 2483436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopaminergic drugs in congestive heart failure: hemodynamic and neuroendocrine responses to ibopamine, dopamine, and dihydroergotoxine.
    Metra M; Missale C; Spano PF; Cas LD
    J Cardiovasc Pharmacol; 1995 May; 25(5):732-40. PubMed ID: 7630152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ibopamine in the treatment of heart failure.
    Man in't Veld AJ
    Am J Med; 1991 May; 90(5B):50S-54S. PubMed ID: 1675552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of ibopamine on heart rate and arrhythmic pattern in patients with congestive heart failure. A double-blind multicentre study.
    G Ital Cardiol; 1989 Jan; 19(1):71-80. PubMed ID: 2663585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ibopamine in chronic congestive heart failure: hemodynamic and neurohumoral effects.
    López-Sendón J
    Am J Med; 1991 May; 90(5B):43S-49S. PubMed ID: 1675551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.